Bardoxolone methyl in type 2 diabetes and advanced chronic kidney disease.

@article{Himmelfarb2014BardoxoloneMI,
  title={Bardoxolone methyl in type 2 diabetes and advanced chronic kidney disease.},
  author={Jonathan Himmelfarb and Katherine R Tuttle},
  journal={The New England journal of medicine},
  year={2014},
  volume={370 18},
  pages={
          1768-9
        }
}
To the Editor: The increased risk of heart failure and cardiovascular events that led to early termination of the BEACON (Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus: the Occurrence of Renal Events) trial, reported by de Zeeuw et al. (Dec. 26 issue),1 may not be due to direct effects of bardoxolone methyl on the cardiovascular system. The transcription factor Nrf2 (nuclear factor [erythroid-derived 2]–related factor 2) is known to regulate… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 19 CITATIONS

Nrf2 at the heart of oxidative stress and cardiac protection.

VIEW 2 EXCERPTS
CITES BACKGROUND

Effects of curcumin in experimental diabetic nephropathy

  • Sharma S. Prabhakar
  • Medicine
  • Journal of investigative medicine : the official publication of the American Federation for Clinical Research
  • 2017

References

Publications referenced by this paper.
SHOWING 1-9 OF 9 REFERENCES